Myasthenia gravis: vizsgálatok itt: Kína
42 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Where
- Beijing, Chengdu, Chongqing, Nanchang, Suzhou
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00 - 3. fázisTaking peopleA Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Where
- Beijing, Chongqing, Nanchang, Suzhou
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07465289 · EU 2025-524757-14-00 - 3. fázisTaking peopleA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Where
- Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an
- Életkor
- 18 év and over
- People
- 199 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00 - Korai 1. fázisNot yet taking people in KínaA Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
- Where
- Wuhan
- Életkor
- 18 év to 65 év
- People
- 12
- Run by
- Daishi Tian
See details and how to joinNCT07917923 - 2. fázisTaking peopleA Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
- Where
- Changsha, Shanghai
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07622342 - 3. fázisTaking peopleEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Where
- Anhui Sheng, Beijing, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou, Zunyi
- Életkor
- 18 év and over
- People
- 264 worldwide
- Run by
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00 - 3. fázisTaking peopleEfficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
- Where
- Beijing, Changchun, Fuzhou, Jinan, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- Életkor
- 18 év to 130 év
- People
- 20
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07596784 - 1/2. fázisTaking peopleSafety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év to 60 év
- People
- 27
- Run by
- Tianjin Medical University General Hospital
See details and how to joinNCT07022197 - 1. fázisNot yet taking people in KínaAn Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
- Where
- Beijing, Shanghai
- Életkor
- 18 év and over
- People
- 18
- Run by
- Shanghai Lanyi Therapeutics Co., Ltd.
See details and how to joinNCT07818291 - 1. fázisTaking peopleClinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
- Where
- Changchun, Chengdu, Fuzhou, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou
- Életkor
- 18 év and over
- People
- 44
- Run by
- Candid Therapeutics
See details and how to joinNCT07215650 - 2/3. fázisTaking peopleA Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- Where
- Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Qingdao, Shanghai, Shenzhen, Wuhan, Xi'an, Zunyi
- Életkor
- 18 év to 70 év
- People
- 104
- Run by
- Shanghai Jiaolian Drug Research and Development Co., Ltd
See details and how to joinNCT06447597 - 1. fázisTaking peopleA Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
- Where
- Jinan
- Életkor
- 18 év to 65 év
- People
- 60
- Run by
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
See details and how to joinNCT06688435 - 1. fázisNot yet taking people in KínaEfficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
- Where
- Hefei
- Életkor
- 18 év to 80 év
- People
- 6
- Run by
- Shenzhen MagicRNA Biotechnology Co., Ltd
See details and how to joinNCT07556120 - No phaseTaking peopleBiomarkers in Autoimmune Disease of Nervous System
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 50 000
- Run by
- Tongji Hospital
See details and how to joinNCT06502015 - 1. fázisNot yet taking people in KínaUniversal STAR-T Cell Injection in Generalized Myasthenia Gravis
- Where
- Wuhan
- Életkor
- 18 év to 65 év
- People
- 10
- Run by
- Daishi Tian
See details and how to joinNCT07714798 - 1. fázisNot yet taking people in KínaA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Where
- Qingdao
- Életkor
- 18 év to 70 év
- People
- 18
- Run by
- The Affiliated Hospital of Qingdao University
See details and how to joinNCT07676266 - No phaseTaking peopleCohort Study on Neuroimmune Diseases in the Reproductive Age
- Where
- Guangzhou
- Életkor
- 20 év to 55 év
- People
- 100
- Run by
- Third Affiliated Hospital, Sun Yat-Sen University
See details and how to joinNCT07653984 - No phaseNot yet taking people in KínaA Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 75
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT07593911 - Korai 1. fázisTaking peopleCD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
- Where
- Wuhan
- Életkor
- 18 év to 70 év
- People
- 36
- Run by
- Tongji Hospital
See details and how to joinNCT07337785 - 1. fázisTaking peopleSafety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 6
- Run by
- Tongji Hospital
See details and how to joinNCT07526493 - 3. fázisTaking peopleA Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
- Where
- Beijing
- Életkor
- 12 év to 80 év
- People
- 120
- Run by
- RemeGen Co., Ltd.
See details and how to joinNCT07249632 - No phaseTaking peopleEfficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
- Where
- Xuzhou
- Életkor
- 18 év to 80 év
- People
- 6
- Run by
- The Affiliated Hospital of Xuzhou Medical University
See details and how to joinNCT07413835 - No phaseTaking peopleClinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
- Where
- Wuhan
- Életkor
- 18 év to 70 év
- People
- 12
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07470151 - No phaseNot yet taking people in KínaA Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
- Where
- Hangzhou, Jinan, Shenzhen
- Életkor
- Up to 18 év
- People
- 30
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07298928 - No phaseTaking peopleRegistry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Where
- Beijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Qingdao, Shijiazhuang
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT04202341